Business Context and Reporting Period
Company: P3 Health Partners Inc. (PIII)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: P3 is a patient-centered, physician-led population health management company operating primarily in the Medicare Advantage (MA) market. It utilizes a capitated, at-risk model where it manages the total cost of care for attributed members in exchange for a percentage of the premium paid by health plans. The company operates in an "Up-C" structure, owning approximately 46% of P3 LLC, which holds substantially all assets and operations.
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Total Operating Revenue | $1,459,080 | $1,500,455 |
| Net Loss | $(323,086) | $(310,378) |
| Net Loss Attributable to Controlling Interest | $(147,948) | $(135,849) |
| Medical Margin (Non-GAAP) | $23,528 | $85,459 |
| Adjusted EBITDA Loss (Non-GAAP) | $(161,276) | $(167,199) |
| Cash and Cash Equivalents (Unrestricted) | $25,012 | $38,816 |
| Total Debt Outstanding | $336,730 | $198,045 |
| Unpaid Claims Liability | $287,790 | $255,089 |
| Premium Deficiency Reserve | $86,116 | $67,368 |
Material Changes vs. Prior Period
- Revenue Decline: Total operating revenue decreased by 3% ($41.4 million) to $1.46 billion. Capitated revenue dropped 4% primarily due to a 7% decrease in average at-risk members (from 126,000 to 116,100) driven by the strategic termination of underperforming payor contracts and affiliate providers.
- Widening Net Loss: Net loss increased by 4% to $323.1 million. While operating expenses decreased slightly, interest expense surged 148% to $55.0 million due to increased principal amounts on unsecured promissory notes.
- Medical Margin Compression: Medical margin (revenue less medical claims) collapsed by 72% to $23.5 million, down from $85.5 million, reflecting the impact of member mix changes and cost management challenges.
- Debt Expansion: Total debt increased significantly by approximately $138.7 million to $336.7 million. This was driven by multiple new promissory notes (VGS 1 through VGS 5) issued throughout 2024 and 2025 to fund operations.
- Asset Sale: The company sold its Florida assets in late 2024 and early 2025, recognizing a net gain of $13.3 million in 2024 and a small loss in 2025.
Guidance, Outlook, Risks, and Contingencies
- Going Concern Warning: Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern for one year following the report date. The company has an accumulated deficit of $651.1 million and expects to require additional funding in 2026.
- Liquidity Status: As of December 31, 2025, the company held $25.0 million in unrestricted cash. It received $18.0 million in related party financing in January and February 2026 but anticipates needing further capital to fund operations and refinance debt.
- Debt Covenants: The company was not in compliance with covenants requiring financial statements free of a "going concern" explanatory paragraph. Lenders granted a waiver for the 2025 fiscal year, but future compliance is not assured.
- Regulatory Risks:
- DOJ Investigation: In June 2024, the company received a Civil Investigative Demand (CID) from the DOJ regarding arrangements with insurance agents and brokers under the False Claims Act.
- California Compliance: The California Department of Managed Health Care (DMHC) determined that Medcore HP (a subsidiary) was not in compliance with tangible net equity requirements as of December 31, 2025, requiring a corrective action plan.
- Nasdaq Listing: The company received a deficiency letter regarding stockholders' equity requirements and has until May 20, 2026, to regain compliance to avoid delisting.
- Outlook: The company expects to continue incurring net losses and negative cash flows from operations for the foreseeable future. Growth strategies include expanding in current markets (Arizona, California, Nevada, Oregon) and entering new geographies, though execution is contingent on capital availability.
Key Facts for Investor Verification
- Capital Sufficiency: Verify the status of the company's efforts to raise additional capital in 2026, given the explicit "substantial doubt" regarding its ability to continue as a going concern.
- Debt Service Capacity: Assess the ability to service $336.7 million in debt with interest rates ranging from 11% to 19.5%, much of which includes Paid-in-Kind (PIK) interest that compounds the principal balance.
- Medical Cost Trends: Monitor the medical margin and claims payable trends, as the company operates on a thin margin where medical expenses exceeded revenue in the aggregate for the year.
- Regulatory Outcomes: Track the resolution of the DOJ investigation and the DMHC corrective action plan, as adverse outcomes could result in significant fines, penalties, or operational restrictions.
- Nasdaq Compliance: Confirm whether the company meets the $2.5 million stockholders' equity requirement by the May 20, 2026 deadline to avoid delisting.